Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

Showing posts for — Year: 2017

08.07.17

EyeGate Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update

WALTHAM, Mass., Aug. 07, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and...
Read more
08.01.17

EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for Cataract Surgery

WALTHAM, Mass., Aug. 01, 2017 -- EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders...
Read more
06.09.17

EyeGate Announces $10.0 Million Public Offering

WALTHAM, Mass., June 09, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders...
Read more
05.22.17

EyeGate Receives Milestone Payment from Valeant Pharmaceuticals for EGP-437 for Post-operative Ocular Inflammation and Pain in Ocular Surgery Patients

WALTHAM, Mass., May 22, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders...
Read more
05.08.17

EyeGate Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update

WALTHAM, Mass., May 08, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and...
Read more
05.04.17

EyeGate Submits Investigational Device Exemption (IDE) Filing for Second Pilot Study of Ocular Bandage Gel

WALTHAM, Mass., May 04, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and...
Read more
03.13.17

EyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, M.D. and Randall J. Olson, M.D.

WALTHAM, Mass., March 13, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases...
Read more
02.23.17

EyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update

Waltham, Mass., Feb. 23, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and...
Read more